|
Medivir develops pharmaceuticals against major, widespread diseases, with its
biggest commitment
currently in the hepatitis C segment. The company engages
in a number of partnerships
with established pharmaceutical companies and
smaller biotechnology enterprises
on clinical and preclinical projects.
Medivir’s objective is to become a profitable pharmaceutical company with
in-
house sales resources on the Nordic market.
The project portfolio includes the pharmaceutical Xerclear, whose NDA
(new drug application)
for Europe and the US has been approved.
Medivir has four projects in phase II and two in phase I. Medivir also runs
several preclinical
projects.
Net sales in 2008 were sek 97.2 m and as of 31 December, the group had
103 employees. The group consists of parent company Medivir AB (publ)
and the subsidiaries Medivir HIV Franchise AB, Medivir Personal AB
and Medivir (UK) Ltd.
Medivir has been listed on Nasdaq OMX Stockholm since 1996.
|
